NL
DE
Alex Garanto (Pediatrics and Human Genetics) together with Anneke den Hollander (Ophthalmology) and Andries van der Meer (UTwente) have received 1,17M€ to develop a retina-on-chip model that allows the identification of molecular, biochemical and functional measurements to characterize disease pathophysiology and assess treatments for iherited retinal diseases, age-related macular degeneration and neurometabolic diseases. This is with the contribution of Boehringer Ingelheim, Locsense, Proefdiervrij and hDMT Organ-on-Chip consortium.
The Partnership programme Human Measurement models 2.0 for research into the treatment and/or prevention of diseases is funded by the Association of Collaborating Health Foundations (SGF) with a public-private-partnership (PPP) allowance made available by Health~Holland (Top Sector Life Sciences & Health), and by ZonMw and NWO Domain AES.
More info about this grant can be found here (in Dutch).
Related news items
Surprisingly dominant cause underlying type I congenital defect of glycosylation
21 October 2021 Alex Garanto, Melissa Bärenfänger, Mirian Janssen, and Dirk Lefeber published a new study, identifying a surprisingly dominant genetic cause underlying type I congenital defect of glycosylation with neuromusculoskeletal phenotypes. read more
Treatment of brain diseases at risk if neuroscientists can no longer conduct their research
5 August 2021 In order to treat brain diseases such as depression, Alzheimer's or ADHD, more research into the brain is needed. read more
Innovative therapy developed for the future treatment of hereditary (deaf)blindness
26 May 2021 Researchers from the department of Otorhinolaryngology, headed by Erwin van Wijk, developed a novel therapeutic strategy to halt the progression or to prevent vision loss in patients as a consequence of USH2A exon 13 mutations. read more
Foundation Fighting Blindness Awards 1.4 million dollars for Rob Collin and Carel Hoyng
29 April 2021 Two researchers from the Radboudumc have received a prestigious award from the Translational Research Acceleration Program of the Foundation Fighting Blindness USA. read more
Rob Collin appointed Professor of Molecular therapy for inherited retinal diseases
3 February 2021 Effective 16 January 2021, molecular geneticist Rob Collin has been appointed Professor of 'Molecular Therapy for Inherited Retinal Diseases' at Radboudumc Radboud University. read more
